Global Immunoglobulin Market Worth USD 24,446.1 Million With a CAGR of 6.56%

A class of glycoprotein molecules known as immunoglobulins, also known as antibodies, are produced by plasma or white blood cells. They act as antibodies by identifying and binding antigens like bacteria or viruses and aiding in their eradication. They are typically found in immune system serum and cells. Their tests help to identify immune deficiencies, allergies, and autoimmune conditions like celiac disease, lupus, and juvenile idiopathic arthritis. Immunoglobulins can currently be divided into several classes based on biological properties, structure, target specificity, and distribution.

Market Dynamics

Increasing Research and Development Drives the Global Market

Research and development (R&D) is a practical tool for growing and improving the business. R&D can lead to commercial innovations. R&D spending will therefore hasten market growth. According to the HIV Indicator Registry, domestic and international resources totaling an estimated USD 21.5 billion would be available to low- and middle-income countries by the end of 2020 for the HIV response. To lower HIV incidence and shorten life expectancy, providing HIV care, treatment, and prevention calls for increased focus, resources, program effectiveness, and efficiency.

Increased R&D is primarily driven by the rising prevalence of HIV, which also fuels market growth and an increase in demand for HIV-related treatments and medications. Due to the rising prevalence of chronic diseases like HIV, there is a consequent increase in the demand for immunoglobulin drugs, which is anticipated to fuel research and development activities and drug discovery initiatives. The market for immunoglobulins under study is expected to expand over the study's forecast period due to the anticipated increase in demand for products used in detection and treatment.

Rising Incidence of Immunodeficiency DiseasesCreates Tremendous Opportunities

The global immunoglobulin market has seen several developments and improvements, which could increase market growth prospects. The increasing demand for immunoglobulins is mainly due to the increase in immunodeficiency diseases. The market is expected to expand due to key players' mergers, acquisitions, and agreements, which will boost market innovation. Market expansion is a significant factor in the immunoglobulin market's growth. Similarly, other market players invested in product development to encourage market growth. For instance, Janssen submitted a Biologics License Application (BLA) to the US Food and Drug Administration in December 2021, seeking approval for teclistamab to treat patients with relapsed or refractory (R/R) multiple myeloma.

Regional Analysis

North America is the most significant revenue contributor and is expected to grow at a CAGR of 6.16% during the forecast period. Consumer awareness of the products used to treat immunodeficiency disorders has increased due to rising healthcare costs. The main driver of market growth in the United States is a rise in clinician preference for immunodeficiency therapies. A high prevalence of hypogammaglobulinemia was found in patients with newly diagnosed, untreated chronic lymphocytic lymphoma (CLL), according to a study by Namrata Singh et al. published in the British Society for Haematology Journal 2020. Chronic lymphocytic lymphoma patients' low IgA or IgE levels have been associated with more advanced stages of the disease (CLL). The US Food and Drug Administration (FDA) also gave the green light in April 2019 to ADMA Biologics Inc. for ASCENIV, a novel intravenous immunoglobulin for treating primary humoral immunodeficiency disease. The factors above should therefore spur market growth over the forecast period. Therefore, considering the factors above, the segment is expected to grow during the forecast period.

Europe is anticipated to grow at a CAGR of 6.89% over the forecast period. Due to the rising incidence of immune deficiency diseases, rising immunoglobulin usage, and increasing research and development expenditures, the immunoglobulin market in Germany is predicted to proliferate. Numerous national clinical studies have been conducted on the immunoglobulin used to treat COVID-19 patients. For instance, more details on neutralizing antibodies and T-cell responses from the Phase 1/2 BNT162b2 trial conducted in Germany in December 2020 were published by Pfizer Inc. and BioNTech SE. The study's conclusions highlight the complex nature of BNT162b2-induced T-cell immunity and demonstrate that BNT162b2 induces a combined adaptive humoral and cellular immune response against SARS-CoV-2. Due to the existence of all the factors above, the market is therefore anticipated to grow significantly over the ensuing years.

Key Highlights

• The immunoglobulin market was valued at USD 13,799.45 million in 2022. It is expected to reach USD 24,446.1 million by 2030, growing at a CAGR of 6.56% during the forecast period (2023–2031).

• Based on the product, the global immunoglobulin market is bifurcated into IgG, IgA, IgM, IgE, and IgD. The IgG segment is the highest contributor to the market and is expected to grow at a CAGR of 6.45% during the forecast period.

• Based on the mode of delivery, the global immunoglobulin market is bifurcated into the intravenous mode of delivery and subcutaneous mode of delivery. The intravenous mode of the delivery segment is the highest contributor to the market and is expected to grow at a CAGR of 6.53% during the forecast period.

• Based on application, the global immunoglobulin market is bifurcated into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, and myasthenia gravis. The immunodeficiency disease segment is the highest contributor to the market and is expected to grow at a CAGR of 6.01% during the forecast period.

• North America is the most significant revenue contributor and is expected to grow at a CAGR of 6.16% during the forecast period.

Market Segments

Global Immunoglobulin Market: Segmentation

By Product

• IgG

• IgA

• IgM

• IgE

• IgD

By Mode of Delivery

• Intravenous Mode of Delivery

• Subcutaneous Mode of Delivery

By Applications

• Hypogammaglobulinemia

• Chronic Inflammatory demyelinating polyneuropathy (CIDP)

• Immunodeficiency Disease

• Myasthenia Gravis

By Regions

• North America

• Europe

• Asia-Pacific

• The Middle East and Africa

• South America